版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Allogeneic haematopoietic cell transplantation for multiplemyelomanThe allogeneic transplant has the advantage over the autologous transplantnThe graft does not contain tumor cells and the potential for a graft versus myeloma (GvM) effectBone marrow transplantation in three patients with multiple my
2、eloma Gahrton G, Ringdn O, Lnnqvist B, Lindquist R, Ljungman P.Acta Med Scand 1986;219(5):523-7.瑞典卡罗林斯卡医学院瑞典卡罗林斯卡医学院 1983Myeloablative conditioning n Three patients with multiple myeloma received bone marrow grafts from HLA-identical sibling donorsn One of the patients, with IgA kappa myeloma, refra
3、ctory to alkeran-prednisone therapy, is well and still without sign of disease 26 months post transplantationn A second patient with Bence-Jones kappa myeloma is well, and skeletal pain and Bence-Jones proteinuria has disappeared 2 months after transplantation.n A third patient with IgG-lambda myelo
4、ma died of effusive pericarditis shortly after transplantation. Acta Med Scand 1986;219(5):523-7Conclusion n Bone marrow transplantation may be indicated in a selective group of patients with multiple myelomaActa Med Scand 1986;219(5):523-7n Out of 690 allogenetic matched sibling donor transplants f
5、or MM n344 were performed during the period 1983-93(all with BM ) group 1n356 during 1994-98 (223 with BM group 2 and 133 with PB group 3)u the median age at transplantation of patients in group 1 was 43 years (range 21-62)uIn group 2 ,44 years (range 18_57) and in group 3, 46 years (range 25_60)u T
6、BI+CY tended to be more commonly used in group 1(37%) and 2 (39%) than in group 3 (27%)uMelphalan containing regimes tended to be morely used in group 3 uMelphalan or Busulphan + CY rarely nConditiong regimeEngraftmentGVHD Treatment related mortalityTreatment related mortalityRelapse rate Relapse ra
7、te SurvivalSurvivalnProgression free survivalu PFS was significantly better for group 2than for group 1(P0.0001)uWith no significantly difference between group 2 and 3nCause of death u 75% in group 1,36% in group 2 ,33 % in group 3 uGVHDuFungal uARDSuOrgan failurenCause of death u the study shows th
8、at the improvement is entirely a result of a lower TRM during the latest 5-years periodu aGVHD has no changed during this peroid uThere was significant difference in deaths caused by IP and bacterial and fungalinfectionConditioning regime u TBI+Melphalan has not previrous been u Shown to be superior
9、 to TBI+CY in this studynconclusion n Survival n 3060%nTreatment related mortalityn30%Myeloablative allogeneic versus autologous transplantationnduring the years 1983 to 1994n189 myeloma patients who underwent allo-BMT with an HLA-identical sibling donor were compared retrospectively with an equal n
10、umber of patients who receivedn a single autologous bone marrow or blood stem cell graftnAnd the ASCT patients were transplanted from 1986 to 1994n conclusionn The overall survival was significantly better for ASCT than for allo-BMT, with a median survival of 34 months and 18 months, respectively (P
11、 = .001), n The main reason for the poorer survival in allo-BMT patients was higher TRM (41% v 13% for ASCT, P = .0001), which was not compensated for by a lower rate of relapse and progressionn conclusionnHowever, in patients alive at 1 year posttransplant, there was a trend for better long-term su
12、rvival (P = .O9) and significantly better progression-free survival (P = .02) for allo-BMT as compared with ASCTnWe conclude that the median survival is superior for ASCTnHowever, allo-BMT has a lower relapse rate, which results in a similar long-term outcome for both approaches, but a longer follow
13、-up is needed to assess the final outcome Reduced-intensity conditioning allogeneic transplantationnThe Allo-RIC was introduced in an attempt to decrease the transplant-related toxicity while retaining the beneficial GvM effectn2019 begin clinical studyn 20192019nWe report the outcome of 229 patient
14、snwho received an allograft for myelomanwith reduced-intensity conditioning (RIC)nregimens from 33 centers within the EBMT.n With a median follow-up of 28 months, 115 patients are alive(range, 1-53 months)n The estimated overall survival at 3 yearsn is 40.6% (CI, 33%-49%) n The treatment-related mor
15、talities at day 100, 1 year,and 2 years were 10%, 22%, and 26%, respectively.n The cumulative probability of the progression-free survival was 21.3% (CI, 15%-29%) at 3years Conclusion While RIC is feasible, heavily pretreated patients and patients with progressive disease do not benefit RIC vs MACnD
16、ata were available on a total of 516 patients from 103 centers: 320 patients with RIC and 196 with MAC.nbetween January 1, 2019, to December 31, 2019nThe median follow-up was 28 monthsnconclusionn RIC was associated with a reduction in TRM but this was offset by an increase in relapse risk nthe cond
17、itioning intensity did not impact on overall survival or retain significance for PFSnThese data suggest that there is a continuing need to investigate dose intensity in the conditioning for myeloma allografts.Tandem autologous/Allo-RIC transplantationn Autologous hematopoietic cell transplantation(H
18、CT) followed by nonmyeloablative allogeneic HCT (auto/alloHCT) provides cytoreduction and graft-versus-myeloma effects. 弗雷德哈钦森癌症研讨中心弗雷德哈钦森癌症研讨中心n Patient inclusion criteria for this analysis were nstage II or III MM at diagnosisn available human leukocyte antigen (HLA)identical sibling donorn progra
19、mmed sequential treatment with conventional autologous HCT followed by nonmyeloablative auto/alloHCT nno prior autologous HCT.n 105 patients with MM fulfilling those criteria were sequentially enrolled at 10 centers on 4 FHCRC-coordinated multiinstitutional protocols from August 2019 to August 2019n
20、 Patients proceeded to allogeneic HCT 40 to 180 days after autograftingn Autologous HCT.n(G-CSF) mobilized peripheral blood mononuclear cells (G-PBMC) were harvested by leukapheresis after treatment with cyclophosphamide 3 to 4 g/m2 (day 1) and G-CSF 10 g/kg subcutaneously (from day 3 through collec
21、tion)n Autologous HCTn38 patients received additional paclitaxel (250 mg/m2 per day, day 2),nand 25 received additional etoposide (200 mg/m2 per day; days 1, 2, 3) nand dexamethasone (10 mg/day orally; days 1, 2,3, 4)nTwo patients received G-CSF alone.n Autologous HCTnNo treatment for MM was given b
22、etween autologous and allogeneic HCTn Allogeneic HCTn After recovery from autologous HCTn102 patientsproceeded to allotransplantation. Donors were HLA-identical siblingsn Nonmyeloablative conditioning consisted in all patients of 2 Gy total body irradiation (TBI) at 7 cGy/min by linear accelerator o
23、r cobalt on day 0n27 patients received additional fludarabine (30 mg/m2) on days 4, 3, and 2N%n EngraftmentnAll 102 allografted patients had sustained engraftment. nOn day 28, medians of 90%, 95%, and 95% of peripheral blood T cells, granulocytes, and nucleated marrow cells,respectively, were of don
24、or origin.nThis increased to medians of 96% to 100% on day 84GVHD43 patients (42%) developed grades 2 to 4 acute GVHD at a median of 42 (range, 8-107) days74 patients (74%) developed chronic extensive GVHD at a median of 167 (range, 90-830) days after transplantation.n NRMnNRM was 1% at day 100 and
25、11%, 14%, and 18% at 1, 2, and 5 years after allografting, respectivelynGVHD and infections were responsible for 18 of 19 non relapse related deaths.n Overall and progression-free survivalsnAfter a median follow-up of 6.3 years after allografting (range 2-9)n60 of 102 (59%)patients survived and 33 o
26、f 102 (32%) are in remissionnFive-year estimated OS and PFS were 64% and 36%,respectivelyn conclusionnauto/allo-RIC HCT is a treatment option for patients with advanced stage MMnThe addition of novel agents (eg,thalidomide, bortezomib, and lenalidomide) as induction or postgrafting therapy, acting w
27、ith GVM effects against disease-specific antigens, might further improve the outcome.n improve the outcomenThalidomide/lenalidomidendexamethasonenBortezomib研讨所佩奥利研讨所佩奥利- Calmettes,马赛,法国,马赛,法国 n This was a retrospective study from 3 centers n 37 patients treated between November 2019 and March 2019n conclusionnbortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT. Double autologous Versus tandem auto/Allo-RIC transplantation圣乔凡尼巴蒂斯塔大学医院,都灵,意大利圣乔凡尼巴蒂斯塔大学医院,都灵,意大利 n
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 《化学电源制造技能训练》教学大纲
- 教案设计(印刷)
- 玉溪师范学院《网球》2021-2022学年第一学期期末试卷
- 玉溪师范学院《商业银行业务与经营》2023-2024学年第一学期期末试卷
- 一片槐树叶课件
- 五下22课教学课件教学
- 深圳市龙华区七年级语文 中段学情检测2024-2025学年第一学期 统编版
- 2024届河北省邯郸市磁县滏滨中学高三1月教学质量检测试题数学试题试卷
- 餐饮底料购销合同范本
- 材料质量要求和质量标准合同
- 新青岛版三上科学19《海洋和陆地》教学设计
- 住宅项目工程总承包(EPC)技术标
- 情绪密码-心理课件
- 《牢固树立国家安全观-国家安全教育学习》教案 第7课 经济安全 国家安全的基础
- 采矿学课件(新)
- 太阳能制氢的能量转换、储存及利用系统
- 光的折射 说课一等奖
- 呼吸衰竭抢救流程
- 运用数学知识解决高中物理问题的探索
- 国开电大本科工程数学(本)在线形考(形成性考核作业4)试题及答案
- 外研版四年级英语上册 (We are going to visit Hainan)教学课件
评论
0/150
提交评论